Christian Hein · 10 September 2024 · 1 min read
$120M Alert: Another significant funding round in AI-driven drug discovery, this time with Lilly...
Another significant $120M funding round has landed in AI-driven drug discovery, this time with Lilly leading alongside Nvidia and key VC funds. I'm optimistic that we could be witnessing the birth of the next Amgen, Genentech, or Biogen — powered by AI.
$120M Alert: Another significant funding round in AI-driven drug discovery, this time with Lilly leading the way!
The surge in investments for AI-enabled biotech and techbio companies continues strong. Recent rounds include Formation Bio, Xaira Therapeutics, and now, Lilly - alongside Nvidia and key VC funds - investing $120M into a company focused on GPCR targets, leveraging a fully virtual screening approach.
Despite challenges faced by companies like Recursion, I believe this is just the beginning. We might be witnessing the birth of the next Amgen, Genentech, or Biogen - the giants that emerged from the molecular biology revolution. Could AI be the driving force behind the next wave of biopharma innovation? I'm optimistic.
Filed under Tech Bio
Artificial Intelligence · Biotech · Tech Bio · Venture Investment · Innovation Management · Strategic Planning · Pre-clinical research
Related insights
16 Dec 2025
OpenAI is among the backers of a biotech founded in 2024 that is already valued at $1.3B.
7 Apr 2026
Anthropic buys Coefficient Bio: why the scientific decision layer matters
26 Mar 2026
Earendil Labs just raised $787M for AI-driven biologics. The largest AI biotech round of 2026 so far.
10 Mar 2026
AI drug discovery benchmarks: why pharma needs model evaluation discipline